Drug profile · INN
relacorilant
LIFYORLI (COPACKAGED)
relacorilant (LIFYORLI (COPACKAGED)) is a glucocorticoid receptor antagonist. Associated with CORCEPT THERAPEUTICS INC. Route of administration: oral. Current US regulatory status: approved.
Drug details — relacorilant
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 17
- Data quality
- 0.89
Quick answer
relacorilant (LIFYORLI (COPACKAGED)) is a glucocorticoid receptor antagonist. Associated with CORCEPT THERAPEUTICS INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor antagonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12336985
Methods for shrinking pituitary tumors
granted -
US 12152028
Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 12097192
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
granted -
US 12005055
Methods for shrinking pituitary tumors
granted -
US 11944617
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
granted -
US 11925626
Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
granted -
US 11684612
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
granted -
US 11590113
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
granted -
US 11576907
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 11464764
Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
granted -
US 11285145
Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
granted -
US 11268145
Methods for treating Cushing's syndrome
granted -
US 11058670
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
granted -
US 10946005
Methods for shrinking pituitary tumors
granted -
US 10456392
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 9273047
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 8889867
Solid forms and process for preparing
granted -
US 8859774
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 8598154
Pyridyl-amine fused azadecalin modulators
granted -
US 8461172
Solid forms and process for preparing
granted
Frequently asked questions
What is relacorilant?
relacorilant (LIFYORLI (COPACKAGED)) is a glucocorticoid receptor antagonist. Associated with CORCEPT THERAPEUTICS INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for relacorilant?
LIFYORLI (COPACKAGED) is a marketed brand name for relacorilant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of relacorilant?
relacorilant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.